For biologic-experienced patients hospitalized with acute severe ulcerative colitis, off-label, high-intensity doses of tofacitinib (Xeljanz) given with intravenous corticosteroids may have reduced ...

When anti–tumor necrosis factor-alpha (anti-TNF) treatment fails to achieve remission for patients with ulcerative colitis (UC), tofacitinib (Xeljanz) appears more effective sooner than vedolizumab ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Patients with rheumatoid arthritis who ...

Re-treatment with tofacitinib after a period of treatment interruption was well tolerated and effective in patients with ulcerative colitis who had shown a previous response to tofacitinib induction, ...

The US Food and Drug Administration approval of tofacitinib (Xeljanz) in November 2012 represents a potential for significant change in the approach to the treatment of rheumatoid arthritis. The US ...

Favorable outcomes were observed among patients with vitiligo who received systemic Janus kinase inhibitors, with tofacitinib associated with the highest rate of complete resolution. Tofacitinib may ...

The appraisal committee (section 5) considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...

Tofacitinib used as add-on therapy to corticosteroids helps reduce need for medical or surgical rescue therapy among patients with acute severe ulcerative colitis. Using tofacitinib as an adjunctive ...

In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist.

Please provide your email address to receive an email when new articles are posted on . Tofacitinib for psoriatic arthritis is efficacious in most patient-reported and clinical endpoints over time, ...

The appraisal committee considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Tofacitinib Global Market Report 2023" - https://www.reportlinker ...